Omalizumab – March 2026

Injection 75 mg in 0.5 mL single dose pre-filled pen, Injection 150 mg in 1 mL single dose pre-filled pen

  • Brand names:
    • Omlyclo®
  • Pharmaceutical Company:
    • CELLTRION HEALTHCARE AUSTRALIA PTY LTD
  • Condition/Indication: Uncontrolled severe asthma. Uncontrolled severe allergic asthma. Severe chronic spontaneous urticaria.
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026